Group B streptococcusserotype prevalence in reproductive-age women at a tertiary care military medical center relative to global serotype distribution

Ippolito, Danielle L; James, Wesley A; Tinnemore, Deborah; Huang, Raywin R; Dehart, Mary J; Williams, Julie; Wingerd, Mark A; Demons, Samandra T

doi:10.1186/1471-2334-10-336

Table 1 Multiple comparisons analysis comparing the Madigan cohort with global GBS serotype distributions.

From: Group B streptococcusserotype prevalence in reproductive-age women at a tertiary care military medical center relative to global serotype distribution

		Serotype Distribution (%)
Region	Patients	Ia	Ib	II	III	IV	V	VI	VII	VIII	NT
Madigan	207	59	25	25	56	4	35	2	0	0	1	#patients
		28.50	12.08	12.08	27.05	1.93	16.91	0.97	0.00	0.00	0.48	%
Canada	353	77	35	40	66	5	78			1	49	#patients
		21.81	9.92	11.33	18.70	1.42	22.10	0.00	0.00	0.28	13.88	%
		0.104	0.512	0.906	0.027	0.918	0.171				0.001	p-value
US	7609	2039	618	826	1887	73	1139	26	3	17	869	#patients
		26.80	8.12	10.86	24.80	0.96	14.97	0.34	0.04	0.22	11.42	%
		0.642	0.055	0.658	0.511	0.299	0.501	0.364			0.001	p-value
Europe	2662	485	329	384	747	98	396	16	16	15	131	#patients
		18.22	12.36	14.43	28.06	3.68	14.88	0.60	0.60	0.56	4.92	%
		0.001	0.93	0.407	0.817	0.265	0.492	0.847			0.006	p-value
ME, EEu	566	78	24	76	82	17	79	10	7	0	41	#patients
		13.78	4.24	13.43	14.49	3.00	13.96	1.77	1.24	0.00	7.24	%
		0.001	0.001	0.709	0.001	0.575	0.363	0.64			0.001	p-value
Asia	1521	171	214	132	446	25	266	81	22	48	85	#patients
		11.24	14.07	8.68	29.32	1.64	17.49	5.33	1.45	3.16	5.59	%
		0.001	0.502	0.142	0.553	0.987	0.913	0.01			0.003	p-value
Africa	260	37	12	22	89	10	82	0	0	0	7	#patients
		14.23	4.62	8.46	34.23	3.85	31.54	0.00	0.00	0.00	2.69	%
		0.001	0.005	0.256	0.118	0.349	0.001				0.142	p-value
S. Am	113	23	12	28	13	2	6				10	#patients
		20.35	10.62	24.78	11.50	1.77	5.31	0.00	0.00	0.00	8.85	%
		0.144	0.836	0.006	0.002	0.749	0.005				0.001	p-value
Mexico	492	277		112	88						16	#patients
		56.30	0.00	22.76	17.89	0.00	0.00	0.00	0.00	0.00	3.25	%
		0.001		0.002	0.009						0.057	p-value
Aus, NZ	125	25	24	5	26	4	37	0		0	2	#patients
		20.00	19.20	4.00	20.80	3.20	29.60	0.00	0.00	0.00	1.60	%
		0.111	0.107	0.022	0.251	0.728	0.01				0.655	p-value

NOTE. Bonferroni correction alpha = 0.05/p = 0.005 (two-sided); statistical significance < 0.005 relative to Madigan cohort
Madigan, Madigan Healthcare System; ME, Middle East; EEu, Eastern Europe; S.Am, South America; Aus, Australia; NZ,New Zealand

Back to article page

ISSN: 1471-2334

Contact us

Submission enquiries: bmcinfectiousdiseases@biomedcentral.com
General enquiries: ORSupport@springernature.com

BMC Infectious Diseases

Contact us